Replies to post #65693 on NanoViricides Inc. (NNVC)

[Ubertino]

But the takings will be in OUR pockets, not big pharma's.

[Puffer]

Your calculation assumes no increase in the number of shares between now and then.

It's a simple calculation based on estimated sales and attaching an industry standard multiple on them. Yes, I would anticipate a bit more dilution but nothing that drastically changes the calculation on share price. After all, I was using the most conservative figures, and valuing the rest of the business at zero.

I estimate that we could charge at least $2200/dose (hopefully only one dose needed) which is what HHS paid Peramivir for its drug that didn't work (under Emergency Use Authorization) during the 2009-10 flu emergency. Because of the DRG payment system, either after US approval or under compassionate use authorization, I think we could charge as much as $5000/dose ..."

So NNVC will charge what the market will bear, just like all those big bad pharmaceutical companies do.

Those are figures on the IV formulation (for hospitalized patients), not oral. I would expect Flucide oral to sell around $150-$200/dose.